Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Metabolic Disorder Therapeutics
... at a CAGR of 6.9% over the analysis period 2024-2030. Diabetes, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$91.9 Billion by the end of the ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Epigenetics
... 18.2% over the analysis period 2024-2030. Epigenetics Kits, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth ... Read More
-
Inflammatory Bowel Disease (IBD) Therapeutics
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. TNF inhibitors, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$14.0 Billion ... Read More
-
Synthetic Biology
... CAGR of 27.9% over the analysis period 2024-2030. Oligonucleotides & Synthetic DNA, one of the segments analyzed in the report, is expected to record a 29.1% CAGR and reach US$39.5 Billion by the end of ... Read More
-
Acute Myeloid Leukemia (AML) Therapeutics
... Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$592.7 Million by ... Read More
-
Small Molecule Drug Discovery
... 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Oncology Therapeutic Area, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$38.9 Billion by ... Read More
-
Hepatitis Therapeutics
... CAGR of 3.7% over the analysis period 2024-2030. Hepatitis C, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.8 Billion by the end of the analysis ... Read More
-
Myasthenia Gravis Treatment
... at a CAGR of 6.3% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.2 Billion by the end of the ... Read More
-
Pathology Instruments
... CAGR of 5.6% over the analysis period 2024-2030. Molecular Diagnostics, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the end of the analysis ... Read More
-
Thin Film Drug Manufacturing
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Oral Thin Film, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.9 Billion by ... Read More
-
Amyloidosis Treatment
... CAGR of 6.8% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.7 Billion by the end of the analysis period. ... Read More
-
Duchenne Muscular Dystrophy Drugs
... 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 35.9% CAGR and reach US$16.5 Billion by the ... Read More
-
Osteoporosis Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$8.1 Billion by the end of the analysis period. ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Botulinum Toxin
... CAGR of 8.8% over the analysis period 2024-2030. Type A, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$11.0 Billion by the end of the analysis ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Pneumonia Therapeutics
... CAGR of 6.7% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$6.8 Billion by the end of the analysis period. ... Read More
-
Hemophilia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Hemophilia A Drugs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$21.3 Billion by the end of the ... Read More
-
Anti-Inflammatory Therapeutics
... CAGR of 4.3% over the analysis period 2024-2030. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$67.7 Billion by the end of the analysis ... Read More
-
Hypercalcemia Treatment
... CAGR of 9.3% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$28.0 Billion by the end of the analysis period. ... Read More
-
Drug Discovery Informatics
... at a CAGR of 9.6% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.4 Billion by the end of ... Read More
-
MRSA Drugs
... CAGR of 4.5% over the analysis period 2024-2030. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$726.5 Million by the end of the ... Read More
-
Gastroparesis Drugs
... CAGR of 4.8% over the analysis period 2024-2030. Idiopathic Gastroparesis Drugs, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
Research Assistance
